Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2015; 140(23): 1775
DOI: 10.1055/s-0041-107750
DOI: 10.1055/s-0041-107750
Fachwissen
Pro & Contra
Pneumokokken-Impfung für Erwachsene unter 60 Jahren? Ja
Pneumococcal Vaccination for Adults – starting before 60? ProFurther Information
Publication History
Publication Date:
03 November 2015 (online)
![](https://www.thieme-connect.de/media/dmw/201523/lookinside/thumbnails/10-1055-s-0041-107750-1.jpg)
Die ambulant erworbene Pneumonie (CAP) ist die häufigste Infektion, die in Deutschland zu einer Hospitalisierung führt, und Pneumokokken sind ihr mit Abstand häufigster Erreger. Sie verursachen zwischen 12–85 % aller CAP-Fälle in Europa [9]. Auch in Deutschland sind Pneumokokken mit 30 % der häufigste CAP-Erreger [7].
-
Literatur
- 1 Andrews NJ, Waight PA, George RC et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30: 6802-6808
- 2 Bonten MJ, Huijts SM, Bolkenbaas M et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372: 1114-1125
- 3 Ewig S, Birkner N, Strauss R et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-1069
- 4 Kuhlmann A, Theidel U, Pletz MW et al. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev 2012; 2: 4
- 5 Mangen MJ, Rozenbaum MH, Huijts SM et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J 2015; DOI: 10.1183/13993003.00325–2015.
- 6 Oviedo-Orta E, Li CK, Rappuoli R. Perspectives on vaccine development for the elderly. Curr Opin Immunol 2013; 25: 529-534
- 7 Pletz MW, von Baum H, van der Linden M et al. The burden of pneumococcal pneumonia – experience of the German competence network CAPNETZ. Pneumologie 2012; 66: 470-475
- 8 Schnoor M, Hedicke J, Dalhoff K et al. Approaches to estimate the population-based incidence of community acquired pneumonia. J Infect 2007; 55: 233-239
- 9 Torres A, Blasi F, Peetermans WE et al. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis 2014; 33: 1065-1079
- 10 Pfizer. Fachinformation zu Prevenar 13 Injektionssuspension. https://www.pfizermed.de/fileadmin/produktdatenbank/pdf/012126_freigabe.pdf Letzter Zugriff am 26.10.15